{"data":[{"accessionNo":"0001346824-26-000237","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001863127","issuerName":"TYRA BIOSCIENCES, INC.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-09-15","reportingPerson":"RA Capital Management, L.P.","reportingCik":"0001346824","personType":"IA,PN","sharesOwned":14130492,"percentOfClass":19.9,"filedAt":"2026-09-17"},{"accessionNo":"0001346824-26-000237","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001863127","issuerName":"TYRA BIOSCIENCES, INC.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-09-15","reportingPerson":"Peter Kolchinsky","reportingCik":"0001384859","personType":"HC,IN","sharesOwned":14130492,"percentOfClass":19.9,"filedAt":"2026-09-17"},{"accessionNo":"0001346824-26-000237","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001863127","issuerName":"TYRA BIOSCIENCES, INC.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-09-15","reportingPerson":"Rajeev Shah","reportingCik":"0001619841","personType":"HC,IN","sharesOwned":14130492,"percentOfClass":19.9,"filedAt":"2026-09-17"},{"accessionNo":"0001346824-26-000237","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001863127","issuerName":"TYRA BIOSCIENCES, INC.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-09-15","reportingPerson":"RA Capital Healthcare Fund, L.P.","reportingCik":"0001315082","personType":"PN","sharesOwned":12115875,"percentOfClass":17.2,"filedAt":"2026-09-17"},{"accessionNo":"0001104659-26-108569","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-09-10","reportingPerson":"Paradigm BioCapital Advisors GP LLC","reportingCik":null,"personType":"OO","sharesOwned":3473453,"percentOfClass":5.8,"filedAt":"2026-09-17"},{"accessionNo":"0001104659-26-108569","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-09-10","reportingPerson":"Senai Asefaw, M.D.","reportingCik":null,"personType":"IN","sharesOwned":3473453,"percentOfClass":5.8,"filedAt":"2026-09-17"},{"accessionNo":"0001104659-26-108569","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-09-10","reportingPerson":"Paradigm BioCapital Advisors LP","reportingCik":null,"personType":"PN","sharesOwned":3473453,"percentOfClass":5.8,"filedAt":"2026-09-17"},{"accessionNo":"0001104659-26-108569","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-09-10","reportingPerson":"Paradigm BioCapital International Fund Ltd.","reportingCik":null,"personType":"CO","sharesOwned":3060595,"percentOfClass":5.1,"filedAt":"2026-09-17"},{"accessionNo":"0001804218-26-000003","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"TYRA BIOSCIENCES, INC.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-06-30","reportingPerson":"Ian Charoub","reportingCik":null,"personType":"IN","sharesOwned":3553585,"percentOfClass":6,"filedAt":"2026-08-14"},{"accessionNo":"0001804218-26-000003","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"TYRA BIOSCIENCES, INC.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-06-30","reportingPerson":"Nextech VI GP S.a. r.l.","reportingCik":null,"personType":"OO","sharesOwned":3553585,"percentOfClass":6,"filedAt":"2026-08-14"},{"accessionNo":"0001804218-26-000003","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"TYRA BIOSCIENCES, INC.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-06-30","reportingPerson":"Nextech VI Oncology SCSp","reportingCik":null,"personType":"PN","sharesOwned":3553585,"percentOfClass":6,"filedAt":"2026-08-14"},{"accessionNo":"0001804218-26-000003","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"TYRA BIOSCIENCES, INC.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-06-30","reportingPerson":"Rocco Sgobbo","reportingCik":null,"personType":"IN","sharesOwned":3553585,"percentOfClass":6,"filedAt":"2026-08-14"},{"accessionNo":"0001804218-26-000003","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"TYRA BIOSCIENCES, INC.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-06-30","reportingPerson":"Costas Constantinides","reportingCik":null,"personType":"IN","sharesOwned":3553585,"percentOfClass":6,"filedAt":"2026-08-14"},{"accessionNo":"0000908834-26-000427","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon F5 (GP), L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14"},{"accessionNo":"0000908834-26-000427","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Healthcare Partners (GP), L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14"},{"accessionNo":"0000908834-26-000427","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Dapice Joshua J.","reportingCik":null,"personType":"HC,IN","sharesOwned":6000,"percentOfClass":0,"filedAt":"2026-08-14"},{"accessionNo":"0000908834-26-000427","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Dreyfuss, Philip D.","reportingCik":null,"personType":"HC,IN","sharesOwned":6000,"percentOfClass":0,"filedAt":"2026-08-14"},{"accessionNo":"0000908834-26-000427","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Dunn Hannah E.","reportingCik":null,"personType":"HC,IN","sharesOwned":6000,"percentOfClass":0,"filedAt":"2026-08-14"},{"accessionNo":"0000908834-26-000427","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Gehani, Varun N.","reportingCik":null,"personType":"HC,IN","sharesOwned":6000,"percentOfClass":0,"filedAt":"2026-08-14"},{"accessionNo":"0000908834-26-000427","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Giauque, Nicolas","reportingCik":null,"personType":"HC,IN","sharesOwned":6000,"percentOfClass":0,"filedAt":"2026-08-14"},{"accessionNo":"0000908834-26-000427","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Husen, Avner A.","reportingCik":null,"personType":"HC,IN","sharesOwned":6000,"percentOfClass":0,"filedAt":"2026-08-14"},{"accessionNo":"0000908834-26-000427","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Kim, David T.","reportingCik":null,"personType":"HC,IN","sharesOwned":6000,"percentOfClass":0,"filedAt":"2026-08-14"},{"accessionNo":"0000908834-26-000427","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Linn, Michael G.","reportingCik":null,"personType":"HC,IN","sharesOwned":6000,"percentOfClass":0,"filedAt":"2026-08-14"},{"accessionNo":"0000908834-26-000427","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Luo Patrick (Cheng)","reportingCik":null,"personType":"HC,IN","sharesOwned":6000,"percentOfClass":0,"filedAt":"2026-08-14"},{"accessionNo":"0000908834-26-000427","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Saito Edric C.","reportingCik":null,"personType":"HC,IN","sharesOwned":6000,"percentOfClass":0,"filedAt":"2026-08-14"},{"accessionNo":"0000908834-26-000427","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Short Daniel S.","reportingCik":null,"personType":"HC,IN","sharesOwned":6000,"percentOfClass":0,"filedAt":"2026-08-14"},{"accessionNo":"0000908834-26-000427","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Spokes, Andrew J. M.","reportingCik":null,"personType":"HC,IN","sharesOwned":6000,"percentOfClass":0,"filedAt":"2026-08-14"},{"accessionNo":"0000908834-26-000427","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Warren, John R.","reportingCik":null,"personType":"HC,IN","sharesOwned":6000,"percentOfClass":0,"filedAt":"2026-08-14"},{"accessionNo":"0000908834-26-000427","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Wehrly, Mark C.","reportingCik":null,"personType":"HC,IN","sharesOwned":6000,"percentOfClass":0,"filedAt":"2026-08-14"},{"accessionNo":"0000908834-26-000427","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Roberts, Jr., Thomas G.","reportingCik":null,"personType":"HC,IN","sharesOwned":6000,"percentOfClass":0,"filedAt":"2026-08-14"},{"accessionNo":"0000908834-26-000427","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital Management, L.L.C.","reportingCik":null,"personType":"IA,OO","sharesOwned":6000,"percentOfClass":0,"filedAt":"2026-08-14"},{"accessionNo":"0000908834-26-000427","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital Partners, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14"},{"accessionNo":"0000908834-26-000427","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital Institutional Partners, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14"},{"accessionNo":"0000908834-26-000427","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital Institutional Partners II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14"},{"accessionNo":"0000908834-26-000427","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital Institutional Partners III, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14"},{"accessionNo":"0000908834-26-000427","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Four Crossings Institutional Partners V, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14"},{"accessionNo":"0000908834-26-000427","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital Offshore Investors II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14"},{"accessionNo":"0000908834-26-000427","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital (AM) Investors, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14"},{"accessionNo":"0000908834-26-000427","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital F5 Master I, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14"},{"accessionNo":"0000908834-26-000427","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Healthcare Partners Master, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14"},{"accessionNo":"0000908834-26-000427","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Partners, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14"},{"accessionNo":"0000908834-26-000427","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Institutional (GP) V, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14"},{"accessionNo":"0002012383-26-003114","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001863127","issuerName":"TYRA BIOSCIENCES INC","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"BlackRock, Inc.","reportingCik":null,"personType":"HC","sharesOwned":2976228,"percentOfClass":5,"filedAt":"2026-07-30"},{"accessionNo":"0001274173-26-000153","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"TYRA BIOSCIENCES, INC","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"JANUS HENDERSON GROUP PLC","reportingCik":null,"personType":"HC","sharesOwned":3890589,"percentOfClass":7.2,"filedAt":"2026-05-15"},{"accessionNo":"0001831942-26-000022","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-31","reportingPerson":"Michael Kramarz","reportingCik":null,"personType":"HC,IN","sharesOwned":2475000,"percentOfClass":4.2,"filedAt":"2026-05-15"},{"accessionNo":"0001831942-26-000022","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-31","reportingPerson":"Robert Egen Atkinson","reportingCik":null,"personType":"HC,IN","sharesOwned":2475000,"percentOfClass":4.2,"filedAt":"2026-05-15"},{"accessionNo":"0001831942-26-000022","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-31","reportingPerson":"Commodore Capital Master LP","reportingCik":null,"personType":"PN","sharesOwned":2475000,"percentOfClass":4.2,"filedAt":"2026-05-15"},{"accessionNo":"0001831942-26-000022","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-31","reportingPerson":"Commodore Capital LP","reportingCik":null,"personType":"IA,PN","sharesOwned":2475000,"percentOfClass":4.2,"filedAt":"2026-05-15"},{"accessionNo":"0001193125-26-224263","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Todd Harris","reportingCik":null,"personType":"IN","sharesOwned":2913342,"percentOfClass":4.8,"filedAt":"2026-05-14"},{"accessionNo":"0000908834-26-000228","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Spokes, Andrew J. M.","reportingCik":null,"personType":"IN","sharesOwned":3580818,"percentOfClass":6.6,"filedAt":"2026-05-12"},{"accessionNo":"0000908834-26-000228","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Dapice Joshua J.","reportingCik":null,"personType":"IN","sharesOwned":3580818,"percentOfClass":6.6,"filedAt":"2026-05-12"},{"accessionNo":"0000908834-26-000228","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Dreyfuss, Philip D.","reportingCik":null,"personType":"IN","sharesOwned":3580818,"percentOfClass":6.6,"filedAt":"2026-05-12"},{"accessionNo":"0000908834-26-000228","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Dunn Hannah E.","reportingCik":null,"personType":"IN","sharesOwned":3580818,"percentOfClass":6.6,"filedAt":"2026-05-12"},{"accessionNo":"0000908834-26-000228","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Gehani, Varun N.","reportingCik":null,"personType":"IN","sharesOwned":3580818,"percentOfClass":6.6,"filedAt":"2026-05-12"},{"accessionNo":"0000908834-26-000228","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Giauque, Nicolas","reportingCik":null,"personType":"IN","sharesOwned":3580818,"percentOfClass":6.6,"filedAt":"2026-05-12"},{"accessionNo":"0000908834-26-000228","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Husen, Avner A.","reportingCik":null,"personType":"IN","sharesOwned":3580818,"percentOfClass":6.6,"filedAt":"2026-05-12"},{"accessionNo":"0000908834-26-000228","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Kim, David T.","reportingCik":null,"personType":"IN","sharesOwned":3580818,"percentOfClass":6.6,"filedAt":"2026-05-12"},{"accessionNo":"0000908834-26-000228","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Linn, Michael G.","reportingCik":null,"personType":"IN","sharesOwned":3580818,"percentOfClass":6.6,"filedAt":"2026-05-12"},{"accessionNo":"0000908834-26-000228","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Luo Patrick (Cheng)","reportingCik":null,"personType":"IN","sharesOwned":3580818,"percentOfClass":6.6,"filedAt":"2026-05-12"},{"accessionNo":"0000908834-26-000228","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Roberts, Jr., Thomas G.","reportingCik":null,"personType":"IN","sharesOwned":3580818,"percentOfClass":6.6,"filedAt":"2026-05-12"},{"accessionNo":"0000908834-26-000228","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Saito Edric C.","reportingCik":null,"personType":"IN","sharesOwned":3580818,"percentOfClass":6.6,"filedAt":"2026-05-12"},{"accessionNo":"0000908834-26-000228","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Short Daniel S.","reportingCik":null,"personType":"IN","sharesOwned":3580818,"percentOfClass":6.6,"filedAt":"2026-05-12"},{"accessionNo":"0000908834-26-000228","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Warren, John R.","reportingCik":null,"personType":"IN","sharesOwned":3580818,"percentOfClass":6.6,"filedAt":"2026-05-12"},{"accessionNo":"0000908834-26-000228","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Wehrly, Mark C.","reportingCik":null,"personType":"IN","sharesOwned":3580818,"percentOfClass":6.6,"filedAt":"2026-05-12"},{"accessionNo":"0000908834-26-000228","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Farallon Partners, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":3407712,"percentOfClass":6.3,"filedAt":"2026-05-12"},{"accessionNo":"0000908834-26-000228","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Farallon Capital Offshore Investors II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":1452596,"percentOfClass":2.7,"filedAt":"2026-05-12"},{"accessionNo":"0000908834-26-000228","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Farallon Capital Institutional Partners, L.P.","reportingCik":null,"personType":"PN","sharesOwned":739107,"percentOfClass":1.4,"filedAt":"2026-05-12"},{"accessionNo":"0000908834-26-000228","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Farallon Capital Partners, L.P.","reportingCik":null,"personType":"PN","sharesOwned":579376,"percentOfClass":1.1,"filedAt":"2026-05-12"},{"accessionNo":"0000908834-26-000228","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Farallon Healthcare Partners (GP), L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":209000,"percentOfClass":0.4,"filedAt":"2026-05-12"},{"accessionNo":"0000908834-26-000228","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Farallon Healthcare Partners Master, L.P.","reportingCik":null,"personType":"PN","sharesOwned":209000,"percentOfClass":0.4,"filedAt":"2026-05-12"},{"accessionNo":"0000908834-26-000228","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Farallon Capital F5 Master I, L.P.","reportingCik":null,"personType":"PN","sharesOwned":173106,"percentOfClass":0.3,"filedAt":"2026-05-12"},{"accessionNo":"0000908834-26-000228","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Farallon F5 (GP), L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":173106,"percentOfClass":0.3,"filedAt":"2026-05-12"},{"accessionNo":"0000908834-26-000228","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Farallon Institutional (GP) V, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":126343,"percentOfClass":0.2,"filedAt":"2026-05-12"},{"accessionNo":"0000908834-26-000228","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Farallon Capital Institutional Partners II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":121341,"percentOfClass":0.2,"filedAt":"2026-05-12"},{"accessionNo":"0000908834-26-000228","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Farallon Capital Institutional Partners III, L.P.","reportingCik":null,"personType":"PN","sharesOwned":105941,"percentOfClass":0.2,"filedAt":"2026-05-12"},{"accessionNo":"0000908834-26-000228","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Four Crossings Institutional Partners V, L.P.","reportingCik":null,"personType":"PN","sharesOwned":126343,"percentOfClass":0.2,"filedAt":"2026-05-12"},{"accessionNo":"0000908834-26-000228","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Farallon Capital (AM) Investors, L.P.","reportingCik":null,"personType":"PN","sharesOwned":74008,"percentOfClass":0.1,"filedAt":"2026-05-12"},{"accessionNo":"0001193125-26-177291","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"COMMON STOCK, $0.0001 PAR VALUE PER SHARE","eventDate":"2026-03-31","reportingPerson":"Canaan Partners XI LLC","reportingCik":null,"personType":"OO","sharesOwned":750000,"percentOfClass":1.4,"filedAt":"2026-04-24"},{"accessionNo":"0001193125-26-177291","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"COMMON STOCK, $0.0001 PAR VALUE PER SHARE","eventDate":"2026-03-31","reportingPerson":"Canaan XI L.P.","reportingCik":null,"personType":"PN","sharesOwned":750000,"percentOfClass":1.4,"filedAt":"2026-04-24"},{"accessionNo":"0001193125-26-177291","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"COMMON STOCK, $0.0001 PAR VALUE PER SHARE","eventDate":"2026-03-31","reportingPerson":"Canaan Partners 2020+ Co-Investment LLC","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-04-24"},{"accessionNo":"0001193125-26-177291","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":"90240B106","securityClass":"COMMON STOCK, $0.0001 PAR VALUE PER SHARE","eventDate":"2026-03-31","reportingPerson":"Canaan 2020+ Co-Investment L.P. - Series 7","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-04-24"},{"accessionNo":"0000315066-26-000723","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001863127","issuerName":"TYRA BIOSCIENCES INC","ticker":"TYRA","cusip":"90240B106","securityClass":"COMMON STOCK","eventDate":"2026-03-31","reportingPerson":"FMR LLC","reportingCik":null,"personType":"HC","sharesOwned":7747647.96,"percentOfClass":14.4,"filedAt":"2026-04-07"},{"accessionNo":"0000315066-26-000723","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001863127","issuerName":"TYRA BIOSCIENCES INC","ticker":"TYRA","cusip":"90240B106","securityClass":"COMMON STOCK","eventDate":"2026-03-31","reportingPerson":"Abigail P. Johnson","reportingCik":null,"personType":"IN","sharesOwned":7747647.96,"percentOfClass":14.4,"filedAt":"2026-04-07"},{"accessionNo":"0001346824-26-000068","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001863127","issuerName":"TYRA BIOSCIENCES, INC.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-04","reportingPerson":"Peter Kolchinsky","reportingCik":"0001384859","personType":"HC,IN","sharesOwned":12266575,"percentOfClass":21.2,"filedAt":"2026-03-06"},{"accessionNo":"0001346824-26-000068","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001863127","issuerName":"TYRA BIOSCIENCES, INC.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-04","reportingPerson":"Rajeev Shah","reportingCik":"0001619841","personType":"HC,IN","sharesOwned":12266575,"percentOfClass":21.2,"filedAt":"2026-03-06"},{"accessionNo":"0001346824-26-000068","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001863127","issuerName":"TYRA BIOSCIENCES, INC.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-04","reportingPerson":"RA Capital Management, L.P.","reportingCik":"0001346824","personType":"IA,PN","sharesOwned":12266575,"percentOfClass":21.2,"filedAt":"2026-03-06"},{"accessionNo":"0001346824-26-000068","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001863127","issuerName":"TYRA BIOSCIENCES, INC.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-04","reportingPerson":"RA Capital Healthcare Fund, L.P.","reportingCik":"0001315082","personType":"PN","sharesOwned":10259291,"percentOfClass":17.7,"filedAt":"2026-03-06"},{"accessionNo":"0000908834-26-000101","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-02-12","reportingPerson":"Warren, John R.","reportingCik":null,"personType":"IN","sharesOwned":2984818,"percentOfClass":5.6,"filedAt":"2026-02-20"},{"accessionNo":"0000908834-26-000101","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-02-12","reportingPerson":"Dapice Joshua J.","reportingCik":null,"personType":"IN","sharesOwned":2984818,"percentOfClass":5.6,"filedAt":"2026-02-20"},{"accessionNo":"0000908834-26-000101","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-02-12","reportingPerson":"Dreyfuss, Philip D.","reportingCik":null,"personType":"IN","sharesOwned":2984818,"percentOfClass":5.6,"filedAt":"2026-02-20"},{"accessionNo":"0000908834-26-000101","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-02-12","reportingPerson":"Dunn Hannah E.","reportingCik":null,"personType":"IN","sharesOwned":2984818,"percentOfClass":5.6,"filedAt":"2026-02-20"},{"accessionNo":"0000908834-26-000101","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-02-12","reportingPerson":"Gehani, Varun N.","reportingCik":null,"personType":"IN","sharesOwned":2984818,"percentOfClass":5.6,"filedAt":"2026-02-20"},{"accessionNo":"0000908834-26-000101","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-02-12","reportingPerson":"Giauque, Nicolas","reportingCik":null,"personType":"IN","sharesOwned":2984818,"percentOfClass":5.6,"filedAt":"2026-02-20"},{"accessionNo":"0000908834-26-000101","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-02-12","reportingPerson":"Husen, Avner A.","reportingCik":null,"personType":"IN","sharesOwned":2984818,"percentOfClass":5.6,"filedAt":"2026-02-20"},{"accessionNo":"0000908834-26-000101","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-02-12","reportingPerson":"Kim, David T.","reportingCik":null,"personType":"IN","sharesOwned":2984818,"percentOfClass":5.6,"filedAt":"2026-02-20"},{"accessionNo":"0000908834-26-000101","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-02-12","reportingPerson":"Linn, Michael G.","reportingCik":null,"personType":"IN","sharesOwned":2984818,"percentOfClass":5.6,"filedAt":"2026-02-20"},{"accessionNo":"0000908834-26-000101","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-02-12","reportingPerson":"Luo Patrick (Cheng)","reportingCik":null,"personType":"IN","sharesOwned":2984818,"percentOfClass":5.6,"filedAt":"2026-02-20"},{"accessionNo":"0000908834-26-000101","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-02-12","reportingPerson":"Roberts, Jr., Thomas G.","reportingCik":null,"personType":"IN","sharesOwned":2984818,"percentOfClass":5.6,"filedAt":"2026-02-20"},{"accessionNo":"0000908834-26-000101","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-02-12","reportingPerson":"Saito Edric C.","reportingCik":null,"personType":"IN","sharesOwned":2984818,"percentOfClass":5.6,"filedAt":"2026-02-20"},{"accessionNo":"0000908834-26-000101","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-02-12","reportingPerson":"Short Daniel S.","reportingCik":null,"personType":"IN","sharesOwned":2984818,"percentOfClass":5.6,"filedAt":"2026-02-20"},{"accessionNo":"0000908834-26-000101","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-02-12","reportingPerson":"Spokes, Andrew J. M.","reportingCik":null,"personType":"IN","sharesOwned":2984818,"percentOfClass":5.6,"filedAt":"2026-02-20"},{"accessionNo":"0000908834-26-000101","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-02-12","reportingPerson":"Wehrly, Mark C.","reportingCik":null,"personType":"IN","sharesOwned":2984818,"percentOfClass":5.6,"filedAt":"2026-02-20"},{"accessionNo":"0000908834-26-000101","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-02-12","reportingPerson":"Farallon Partners, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":2828865,"percentOfClass":5.3,"filedAt":"2026-02-20"},{"accessionNo":"0000908834-26-000101","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-02-12","reportingPerson":"Farallon Capital Offshore Investors II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":1272095,"percentOfClass":2.4,"filedAt":"2026-02-20"},{"accessionNo":"0000908834-26-000101","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-02-12","reportingPerson":"Farallon Capital Institutional Partners, L.P.","reportingCik":null,"personType":"PN","sharesOwned":650679,"percentOfClass":1.2,"filedAt":"2026-02-20"},{"accessionNo":"0000908834-26-000101","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-02-12","reportingPerson":"Farallon Capital Partners, L.P.","reportingCik":null,"personType":"PN","sharesOwned":505122,"percentOfClass":0.9,"filedAt":"2026-02-20"},{"accessionNo":"0000908834-26-000101","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-02-12","reportingPerson":"Farallon Capital F5 Master I, L.P.","reportingCik":null,"personType":"PN","sharesOwned":155953,"percentOfClass":0.3,"filedAt":"2026-02-20"},{"accessionNo":"0000908834-26-000101","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-02-12","reportingPerson":"Farallon F5 (GP), L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":155953,"percentOfClass":0.3,"filedAt":"2026-02-20"},{"accessionNo":"0000908834-26-000101","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-02-12","reportingPerson":"Farallon Institutional (GP) V, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":120497,"percentOfClass":0.2,"filedAt":"2026-02-20"},{"accessionNo":"0000908834-26-000101","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-02-12","reportingPerson":"Four Crossings Institutional Partners V, L.P.","reportingCik":null,"personType":"PN","sharesOwned":120497,"percentOfClass":0.2,"filedAt":"2026-02-20"},{"accessionNo":"0000908834-26-000101","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-02-12","reportingPerson":"Farallon Capital Institutional Partners III, L.P.","reportingCik":null,"personType":"PN","sharesOwned":94197,"percentOfClass":0.2,"filedAt":"2026-02-20"},{"accessionNo":"0000908834-26-000101","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-02-12","reportingPerson":"Farallon Capital Institutional Partners II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":120651,"percentOfClass":0.2,"filedAt":"2026-02-20"},{"accessionNo":"0000908834-26-000101","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share (the \"Shares\")","eventDate":"2026-02-12","reportingPerson":"Farallon Capital (AM) Investors, L.P.","reportingCik":null,"personType":"PN","sharesOwned":65624,"percentOfClass":0.1,"filedAt":"2026-02-20"},{"accessionNo":"0000921895-26-000475","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"BVF PARTNERS L P/IL","reportingCik":null,"personType":"IA,PN","sharesOwned":2127665,"percentOfClass":4,"filedAt":"2026-02-17"},{"accessionNo":"0000921895-26-000475","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"BVF INC/IL","reportingCik":null,"personType":"CO","sharesOwned":2127665,"percentOfClass":4,"filedAt":"2026-02-17"},{"accessionNo":"0000921895-26-000475","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"LAMPERT MARK N","reportingCik":null,"personType":"IN","sharesOwned":2127665,"percentOfClass":4,"filedAt":"2026-02-17"},{"accessionNo":"0000921895-26-000475","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"BVF GP HOLDINGS LLC","reportingCik":null,"personType":"OO","sharesOwned":1964961,"percentOfClass":3.7,"filedAt":"2026-02-17"},{"accessionNo":"0000921895-26-000475","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"BIOTECHNOLOGY VALUE FUND L P","reportingCik":null,"personType":"PN","sharesOwned":1135053,"percentOfClass":2.1,"filedAt":"2026-02-17"},{"accessionNo":"0000921895-26-000475","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"BVF I GP LLC","reportingCik":null,"personType":"OO","sharesOwned":1135053,"percentOfClass":2.1,"filedAt":"2026-02-17"},{"accessionNo":"0000921895-26-000475","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"BVF II GP LLC","reportingCik":null,"personType":"OO","sharesOwned":829908,"percentOfClass":1.6,"filedAt":"2026-02-17"},{"accessionNo":"0000921895-26-000475","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"BIOTECHNOLOGY VALUE FUND II LP","reportingCik":null,"personType":"PN","sharesOwned":829908,"percentOfClass":1.6,"filedAt":"2026-02-17"},{"accessionNo":"0000921895-26-000475","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"BVF Partners OS Ltd.","reportingCik":null,"personType":"CO","sharesOwned":130502,"percentOfClass":0.2,"filedAt":"2026-02-17"},{"accessionNo":"0000921895-26-000475","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"Biotechnology Value Trading Fund OS LP","reportingCik":null,"personType":"PN","sharesOwned":130502,"percentOfClass":0.2,"filedAt":"2026-02-17"},{"accessionNo":"0001193125-26-051409","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"COMMON STOCK, $0.0001 PAR VALUE PER SHARE","eventDate":"2025-12-31","reportingPerson":"Canaan Partners XI LLC","reportingCik":null,"personType":"OO","sharesOwned":2930444,"percentOfClass":5.5,"filedAt":"2026-02-13"},{"accessionNo":"0001193125-26-051409","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"COMMON STOCK, $0.0001 PAR VALUE PER SHARE","eventDate":"2025-12-31","reportingPerson":"Canaan XI L.P.","reportingCik":null,"personType":"PN","sharesOwned":2930444,"percentOfClass":5.5,"filedAt":"2026-02-13"},{"accessionNo":"0001193125-26-051514","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Todd Harris","reportingCik":null,"personType":"IN","sharesOwned":2814379,"percentOfClass":5.1,"filedAt":"2026-02-13"},{"accessionNo":"0001193125-26-051409","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"COMMON STOCK, $0.0001 PAR VALUE PER SHARE","eventDate":"2025-12-31","reportingPerson":"Canaan Partners 2020+ Co-Investment LLC","reportingCik":null,"personType":"OO","sharesOwned":443885,"percentOfClass":0.8,"filedAt":"2026-02-13"},{"accessionNo":"0001193125-26-051409","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"COMMON STOCK, $0.0001 PAR VALUE PER SHARE","eventDate":"2025-12-31","reportingPerson":"Canaan 2020+ Co-Investment L.P. - Series 7","reportingCik":null,"personType":"PN","sharesOwned":443885,"percentOfClass":0.8,"filedAt":"2026-02-13"},{"accessionNo":"0001831942-25-000025","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-09-30","reportingPerson":"Robert Egen Atkinson","reportingCik":null,"personType":"HC,IN","sharesOwned":3375000,"percentOfClass":6.3,"filedAt":"2025-11-14"},{"accessionNo":"0001831942-25-000025","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-09-30","reportingPerson":"Commodore Capital Master LP","reportingCik":null,"personType":"PN","sharesOwned":3375000,"percentOfClass":6.3,"filedAt":"2025-11-14"},{"accessionNo":"0001831942-25-000025","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-09-30","reportingPerson":"Commodore Capital LP","reportingCik":null,"personType":"IA,PN","sharesOwned":3375000,"percentOfClass":6.3,"filedAt":"2025-11-14"},{"accessionNo":"0001831942-25-000025","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-09-30","reportingPerson":"Michael Kramarz","reportingCik":null,"personType":"IA,IN","sharesOwned":3375000,"percentOfClass":6.3,"filedAt":"2025-11-14"},{"accessionNo":"0000902664-25-004987","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Vestal Point Capital, LP","reportingCik":null,"personType":"IA,PN","sharesOwned":2425000,"percentOfClass":4.5,"filedAt":"2025-11-14"},{"accessionNo":"0000902664-25-004987","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001863127","issuerName":"Tyra Biosciences, Inc.","ticker":"TYRA","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Ryan Wilder","reportingCik":null,"personType":"HC,IN","sharesOwned":2425000,"percentOfClass":4.5,"filedAt":"2025-11-14"}],"updatedAt":"2026-09-20T06:58:56.238Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data"}